- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07689279
Selection of Transcatheter Heart vaLve With Intermediate Sizing in Patients With Severe Aortic Stenosis Treated With Transcatheter Aortic Valve Replacement (SELECT TAVR)
Selection of transcathEter Heart vaLve With intermEdiate Sizing in Patients With Severe aortiC Stenosis Treated With Transcatheter Aortic Valve Replacement
Transcatheter aortic valve implantation (TAVI) has evolved into a standard therapy for severe aortic stenosis across all surgical risk profiles, supported by pivotal trials in high- and low-risk populations. Two types of transcatheter heart valves, balloon-expandable and self-expanding, exhibit distinct hemodynamic and structural characteristics that influence procedural strategy and long-term durability. Accurate valve sizing is crucial for procedural success, as both undersizing and oversizing are associated with procedural complications, including aortic regurgitation, conduction disorders, valve embolization, annular rupture, and increased leaflet stress which may impair long-term durability. However, optimal annular sizing remains challenging due to the complex three-dimensional anatomy of the aortic annulus, which is oval, crown-shaped, dynamically deforming, and variably oriented. These anatomical features often lead to "grey zones" in clinical sizing charts, resulting in so-called borderline annuli in which the measured annular dimensions may indicate two suitable valve sizes. Borderline annuli are frequently encountered in patients undergoing TAVI with self-expanding valves (i.e., Evolut transcatheter heart valve series) due to a limited number of sizes (23, 26, 29 and 34 mm). Consequently, under- or oversizing of self-expanding valves is often required. However, sizing of transcatheter heart valves in borderline annuli is associated with a greater likelihood of procedural complications, higher rates of aortic regurgitation, and higher transvalvular gradients.9,11 New generation balloon-expandable valves (i.e., Myval transcatheter heart valve series) are introduced with intermediate (21.5, 24.5, 27.5 mm) and extra-large (30.5, 32 mm) valve sizes that are not available for the Evolut platform. These additional size ranges potentially offer more precise annular sizing, reducing the need for under- or oversizing and improving short- and long-term hemodynamic performance.
The SELECT TAVR trial will evaluate whether the expanded size range of the balloon-expandable Myval transcatheter heart valves is noninferior compared to the self-expanding Evolut transcatheter heart valve series in patients with borderline annular dimensions undergoing TAVI with respect to the composite safety end point of the third Valve Academic Research Consortium (VARC-3) at 30 days.
Objectives:
The primary objective of the current trial is to determine whether the Myval transcatheter heart valve series is noninferior to the Evolut transcatheter heart valve series in patients with borderline annular dimensions undergoing TAVI with respect to the composite safety end point of the third Valve Academic Research Consortium (VARC-3) at 30 days Secondary objectives: The secondary objectives of the current trial include: 1) Hemodynamic performance as assessed by invasive hemodynamic parameters as well as by transthoracic echocardiography at 30 days (+2 months), and longer-term follow-up; and 2) Long-term clinical outcomes with follow-up up to 5 years.
Study design:
The proposed SELECT TAVR trial is an investigator-initiated, open-label, multicenter, randomized controlled, noninferiority trial with blind end point adjudication.
Study population:
The SELECT TAVR trial will focus on patients referred for TAVI in whom CT-derived annular dimensions fall within borderline annulus ranges
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Elsbeth C. Noppers, MD
- Telefonnummer: +31 (0) 20 566 2893
- E-post: e.c.noppers@amsterdamumc.nl
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
A potential participant is deemed eligible for trial participation if the following criteria are met:
- TAVI as decided by local multidisciplinary heart team
CT-derived annular perimeters fall within the following ranges:
- 55.5 - 57.5 mm
- 61.0 - 64.5 mm
- 70.5 - 74.0 mm
- 79.5 - 84.0 mm
- 92.0 - 96.0 mm
- Written informed consent
Exclusion Criteria:
A potential participant will be excluded from trial participation in case of inability to provide informed consent.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Self-expanding Evolut transcatheter heart valve series
|
All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis.
This is a routine medical procedure, not a study intervention.
Andra namn:
|
|
Experimentell: Balloon-expandable Myval transcatheter heart valve series
|
All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis.
This is a routine medical procedure, not a study intervention.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
A composite safety end point as per VARC-3 guidelines
Tidsram: 30 days
|
A composite safety end point as per VARC-3 guidelines that consists of all-cause mortality, all stroke, type 2 to 4 bleeding, major vascular access-related or cardiac structural complications, acute kidney injury stage 3 to 4, moderate or severe aortic regurgitation, new permanent pacemaker implantation due to conduction abnormalities, surgery or intervention related to the device at 30 days after TAVI as defined in accordance with criteria stated by the third Valve Academic Research Consortium (VARC-3).
|
30 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
A composite safety endpoint as per VARC-3 guidelines
Tidsram: Annually, up to 5 years
|
All clinical end points will be assessed after TAVI
|
Annually, up to 5 years
|
|
Hemodynamic performance
Tidsram: At 30 days (+2 months) and at 1, 3 and 5 years
|
Hemodynamic performance will be assessed by transthoracic echocardiography
|
At 30 days (+2 months) and at 1, 3 and 5 years
|
|
Patient-reported outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ)-12
Tidsram: Yearly, up to 5 years
|
Yearly, up to 5 years
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Ronak Delewi, Prof. Dr., Amsterdam University Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Aortaklaffssjukdom
- Hjärt-kärlsjukdomar
- Hjärtsjukdom
- Hjärtklaffssjukdomar
- Ventrikulärt utflödeshinder
- Aortaklaffstenos
- Kirurgiska ingrepp, operativ
- Hjärtkirurgiska ingrepp
- Hjärtkirurgiska ingrepp
- Thoraxkirurgiska ingrepp
- Protesimplantation
- Hjärtventilprotesimplantation
- Transkateter aortaventilersättning
Andra studie-ID-nummer
- NL-011489
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .